Date of Award


Degree Type


Degree Name

Master of Science




Locally advanced breast cancer (LABC) is an aggressive form of pre- metastatic breast cancer, with an expected five-year survival rate of 30-42%. The current standard of treatment is neoadjuvant therapy; however there is a limited ability to monitor tumor response to this treatment. This study looks at two innovative approaches to monitoring tumor response: measurement of plasma osteopontin (OPN) levels and three dimensional ultrasound imaging (3D US). Using our laboratory’s in house ELISA, we found that 39% of LABC patients had plasma OPN levels elevated above the normal healthy range of I23ng/ml (Bramwell,20o6). Over treatment this percent increased, such that at final cycle, 63% patients had elevated OPN levels. Plasma OPN levels at the final two cycles of treatment were significantly different from early levels (p



To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.